Immunotherapy for gastric cancer: a 2021 update-Reference-Cited by-同舟云学术

Immunotherapy for gastric cancer: a 2021 update

Published:2022-01 Issue:1 Volume:14 Page:41-64
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Kole Christo¹^ORCID,Charalampakis Nikolaos²^ORCID,Tsakatikas Sergios²^ORCID,Kouris Nikolaos-Iasonas¹^ORCID,Papaxoinis George³^ORCID,Karamouzis Michalis V⁴^ORCID,Koumarianou Anna⁵^ORCID,Schizas Dimitrios¹^ORCID

Affiliation:

1. First Department of Surgery, National & Kapodistrian University of Athens, Laikon General Hospital, Athens, 115 27, Greece

2. Department of Medical Oncology, Metaxa Cancer Hospital, Athens, 185 37, Greece

3. Second Department of Medical Oncology, Agios Savas Anticancer Hospital, Athens, 115 22, Greece

4. Molecular Oncology Unit, Department of Biological Chemistry, National & Kapodistrian University of Athens, Athens, 115 27, Greece

5. Hematology Oncology Unit, Fourth Department of Internal Medicine, National & Kapodistrian University of Athens, Attikon University Hospital, Athens, 124 62, Greece

Abstract

Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths, accounts for a devastating death rate worldwide. Since the majority of patients with gastric cancer are diagnosed at advanced stages, they are not suitable for surgery and present with locally advanced or metastatic disease. Recent advances in immunotherapy have elicited a considerable amount of attention as viable therapeutic options for several cancer types. This work presents a summary of the currently ongoing clinical trials and critically addresses the efficacy of a large spectrum of immunotherapy approaches in the general population for gastric cancer as well as in relation to tumor genetic profiling.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2021-0103

Reference184 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Two distinct etiologies of gastric cardia adenocarcinoma: interactions among pH, Helicobacter pylori, and bile acids

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

5. Historical Perspective on Familial Gastric Cancer

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MARK4 promotes the malignant phenotype of gastric cancer through the MAPK/ERK signaling pathway;Pathology - Research and Practice;2024-09

2. Inflammation-Related Gene ADH1A Regulates the Polarization of Macrophage M1 and Influences the Malignant Progression of Gastric Cancer;Journal of Inflammation Research;2024-07

3. CD39hi identifies an exhausted tumor-reactive CD8+ T cell population associated with tumor progression in human gastric cancer;Pharmacological Research;2024-04

4. N⁶-methylation in the development, diagnosis, and treatment of gastric cancer;Journal of Translational Internal Medicine;2024-02-01

5. Circular RNA ACTN4 (CircACTN4) Promotes Epithelial-Mesenchymal Transition and Angiogenesis in Gastric Cancer Cells;J BIOL REG HOMEOS AG;2024